Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of preservative-free tafluprost (Saflutan) on intraocular pressure in glaucoma or ocular hypertension
2013-003157-16Phase 4Completed
- Sponsor
- Ordination Dr. Andreas Hommer
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafluprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Ordination Dr. Andreas Hommer. Primary endpoint: Intraocular pressure reduction. Started Aug 2013; status: completed.
02
Drugs
tafluprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2013-003157-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003157-16.